Global Oncolytic Virotherapy Market Size, Forecast, and Trend Highlights Over 2025-2037
Oncolytic Virotherapy Market size is projected to grow from USD 23.09 million to USD 490.46 million, witnessing a CAGR of over 26.5% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of oncolytic virotherapy is estimated at USD 27.99 million.
The reason behind the growth is impelled by the increasing prevalence of cancer globally. According to the World Health Organization in February 2024, there will be over 35 million new cancer cases by 2050. There has been a surge in clinical trials and approval of new virus therapies for cancer treatment. In advanced melanoma, oncolytic viruses (OVs) are used in therapies to attack and destroy tumor cells and are being used to treat cancer.
Additionally, the rising advancements in virology are also fueling the growth of the oncolytic virotherapy market. For instance, in January 2025, the National Institute of Health awarded USD 20 million to fund the human virus research center led by Gilling School. These efforts are creating new anticancer techniques effective against a variety of malignancies.
Oncolytic Virotherapy Sector: Growth Drivers and Challenges
Growth Drivers
- Surge in demand for personalized medicine: According to data published by The Personalized Medicine Coalition in February 2024, personalized medicine topped 1/3rd of new US Food and Drug Administration drug approvals for the 4th year in a row. Oncolytic Virotherapy-based personalized medicine has revolutionized oncology management by better targeting a person’s cancer, resulting in improved outcomes. The rising demand for personalized medicines for cancer treatment is fueling the growth of the market during the assessed time.
- Rising geriatric population: According to research conducted by the Union for International Cancer Control in February 2024, older adults aged 65 years and above, are 11 times more susceptible to developing cancer in comparison to younger people. Also, the United Nations predicts that the world population is projected to reach 9.8 billion in 2050. Oncolytic virotherapy provides promising treatment options for tumors in the old age population, further boosting the market growth.
- Increasing expenditure in cancer research: There has been a rising emphasis on studying cancer to make effective and safe methods to detect, prevent, diagnose, treat, and cure various types of cancer. American Association for Cancer Research in December 2024 stated that oncology research and development through clinical trials has grown to USD 80 billion annually.
Challenges
- Side effects of therapy: Oncolytic viruses occasionally may contaminate healthy cells and excite overall immune movement. Also, there is a potential risk of infection in conducting therapy. The common side effects are chills, fatigue, flu-like indications, injection site pain, sickness, and fever. There are also chances of immunogenicity and resistance to the treatment.
- Lack of professionals to conduct therapy: The therapy is in the nascent stage and only a few professionals are able to conduct it efficiently. However, with the rising emphasis from the government, a greater number of oncologists are gearing up to give effective treatment.
Oncolytic Virotherapy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
26.5% |
|
Base Year Market Size (2024) |
USD 23.09 million |
|
Forecast Year Market Size (2037) |
USD 490.46 million |
|
Regional Scope |
|
Oncolytic Virotherapy Segmentation
Therapy Type (HSV-based, Adenovirus-based, Reovirus, Poxviruses, NDV)
The HSV-based oncolytic virotherapy market is estimated to gain a robust revenue share of about 30%. The growth of the market can be attributed to the large number of clinical trials related to HSV-based viruses. There are 2 existing variants that are HSV Type 1 (HSV-1) and HSV Type 2 (HSV-2). Among these two existing variants HSV-1 has been widely investigated in cancer oncolytic viral therapy. According to the National Institutes of Health in 2023, an estimated 3.7 billion people under age 60 have HSV-1 infection globally. Furthermore, genomic manipulation, cytotoxicity, pathogenicity, and the availability of antiviral drugs have resulted in the growing demand for oncolytic HSV-1 widely as a therapeutic approach to melanoma.
End-User (Hospitals, Specialty Clinics, Cancer Research Institutes)
The hospital segment in the oncolytic virotherapy market is set to garner a notable share in the near future as most of the patients approach hospital facilities for treatment. Cancer patients receive an early diagnosis in hospitals, and the survival rate and chances for successful treatment increase significantly. According to the World Economic Forum in 2024, the hospital sector is projected to reach USD 5.19 trillion by 2029.
Our in-depth analysis of the global oncolytic virotherapy market includes the following segments:
|
Therapy type |
|
|
Virus Type |
|
|
Indication |
|
|
Demography |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportOncolytic Virotherapy Industry - Regional Synopsis
North America Market Forecast
The oncolytic virotherapy market in North America is predicted to account for the largest share of about 39% by the end of 2037, impelled by the growing clinical activities. There has been increased investment in oncology in the region. For instance, in May 2022, the American Institute for Cancer Research funded more than USD 110 million for research through a grant program and federal investment for cancer research in the U.S. Additionally, Innovation, Science, and Economic Development Canada stated that Canada captured 4% of global clinical trials, second to the U.S.
Europe Market Statistics
The Europe oncolytic virotherapy market is estimated to be the second largest, during the forecast timeframe due to rising approvals of oncolytic virotherapy drugs. Also, a data published by the European Commission in 2021, cancer was the 2nd leading cause of death in the European Union. Also, the region has increased investment in research and development. For instance, in Germany, a total of 34 cancer researchers were funded with USD 4.5 million in May 2024.
Companies Dominating the Oncolytic Virotherapy Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Shanghai Sunway Biotech Co. Ltd.
- Oncolys BioPharma Inc.
- TILT Biotherapeutics Ltd.
- Oncorus Inc
- TAKARA BIO INC.
- Vyriad
- Transgene SA
- Lokon Pharma AB
- Pfizer Inc.
- Rigvir Group
- Sibiono GeneTech Co. Ltd.
- Oncolytics Biotech
- Daiichi Sankyo
- Kissei Pharmaceutical Co., Ltd.
- Boehringer Ingelheim
The competitive landscape of the oncolytic virotherapy market is rapidly evolving as established key players, healthcare giants, and new entrants are investing in novel technologies. Key players in the market are focused on developing new technologies and products catering to the stringent regulatory norms and consumer demand. These key players are adopting several strategies such as mergers and acquisitions, joint ventures, partnerships, and novel product launches to enhance their product base and strengthen their market position. Here are some key players operating in the global oncolytic virotherapy market:
In the News
- In February 2025, Oxford-based biotech company Theolytics is leading a new frontier in cancer treatment. The company is harnessing the power of oncolytic viruses to selectively target tumors while saving healthy tissue.
- In January 2025, Novotech joined hands with mid-size pharma companies to accelerate the development of novel and advanced therapeutics. The company has released its report on oncolytic virotherapy named Global Clinical Trial Landscape 2024.
Author Credits: Radhika Pawar
- Report ID: 2988
- Published Date: Mar 06, 2025
- Report Format: PDF, PPT
